Determination of the validity, reliability, and sensitivity of the BETY- Biopsychosocial Questionnaire in patients with a diagnosis of rheumatoid arthritis

Öz

Purpose: This study was planned to determine the validity, reliability, and responsiveness of the BETY- Biopsychosocial Questionnaire (BETY-BQ) in patients with Rheumatoid Arthritis (RA).
Methods: 150 patients with a mean age of 50.6±9.3 were included in the study. The Health Assessment Questionnaire, Rheumatoid Arthritis Quality of Life Scale, Short Form-36 and Hospital Anxiety and Depression Scale were used for validity of the BETY-BQ. The test-retest method and Intraclass Correlation Coefficient (ICC) were used for reliability. The Cronbach alpha coefficient was also used for internal consistency. For the responsiveness of the scale, the correlation of the differences of the BETY-BQ with all scales was checked after for 3 months BETY exercise group.
Results: The Pearson correlation coefficient of BETY-BQ with other scales was found between (r) [-0.361; 0.814], p <0.001. The correlation between the responses of 30 patients to the BETY-BQ for 1 week (r= 0.834; p<0.001), ICC coefficient (0.833, p<0.001) and The Cronbach alpha coefficient (0.937) were significantly high. The responsiveness to change of the BETY-BQ was especially highly correlated with Rheumatoid Arthritis Quality of Life Scale (r= 0.619; p <0.001).
Conclusion: It was concluded that the patients involved in the BETY group being routinely made for 3 months were susceptible to change. As a result of our study, it was concluded that the BETY-BQ is a valid, reliable, and responsive assessment tool for RA patients.

BETY - Biyopsikososyal Ölçeği’nin romatoit artrit tanısı alan bireylerde geçerliği, güvenirliği ve duyarlılığının belirlenmesi

Öz

Amaç: Bu çalışma romatoid artrit (RA) tanılı bireylerde Bilişsel Egzersiz Terapi Yaklaşımı ölçeğinin (BETY-BQ) geçerlik, güvenirlik ve duyarlılığının belirlenmesi amacıyla planlandı.
Yöntem: Çalışmaya yaş ortalaması 50,6±9,3 yıl olan 150 birey dahil edildi. BETY-BQ geçerliği için, Sağlık Değerlendirme Anketi, Romatoid Artrit Yaşam Kalite Ölçeği, Kısa Form-36 ve Hastane Anksiyete ve Depresyon Skalası ölçekleri kullanıldı. Güvenirlik için test-tekrar test yöntemi ile Sınıf İçi Güvenirlik (ICC) katsayısına ayrıca iç tutarlılık için Cronbach alfa katsayısına bakıldı. Ölçeğin duyarlılığı için 3 ay sonra tüm ölçeklerle BETY-BQ’nun zamana bağlı değişimlerinin korelasyonuna bakıldı.
Bulgular: BETY-BQ’nun diğer ölçeklerle arasındaki korelasyon katsayısı (r) [-0,361; 0,814] arasında, p<0,001 bulundu. 1 hafta arayla 30 bireyin BETY-BQ’ya verdiği yanıtların Pearson korelasyon katsayısı (r= 0,834; p<0,001), ICC katsayısı (0,833, p<0,001) ve ölçeğin iç tutarlılığının oldukça yüksek olduğu (Cronbach alfa=0,937) bulundu. Ölçeğin değişime duyarlılığında özellikle Romatoid Artrit Yaşam Kalite ölçeği ile yüksek ilişkili (r= 0,619; p <0,001) bulundu. 3 ay boyunca rutin yapılmakta olan BETY grubuna dahil olan bireylerde değişime duyarlı olduğu sonucuna varıldı.
Sonuç: Çalışmamızın sonucunda BETY-BQ’nun RA’lı bireylerde geçerli, güvenilir ve duyarlı bir değerlendirme aracı olduğu görüşüne varıldı.

Anahtar Kelimeler

• Romatoid artrit
• geçerlik
• güvenirlik
• duyarlılık

Kaynakça

1. 1. Meisters, R, Putrik P, Ramiro, S, et al. "EULAR/eumusc. net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries Ann. Rheum. Dis. 2020;79:1423-1431.
2. 2. Frade-Sosa B, Narváez J, Salman-Monte TC, et al. A comparative study on clinical and serological characteristics between patients with rhupus and those with systemic lupus erythematosus and rheumatoid arthritis. Lupus. 2020;29:1216-1226.
3. 3. Yamanaka H. Diagnosis and treatment of rheumatoid arthritis: toward the best practice. How to use the guideline in the management of rheumatoid arthritis. Clin. Calcium. 2018;28:607-610.
4. 4. Nash P. 2019 update: EULAR RA management recommendations, efficacy and safety systematic literature reviews. Ann Rheum Dis. 2020;79:679-680.
5. 5. Geenen R, Dures E. A biopsychosocial network model of fatigue in rheumatoid arthritis: a systematic review. Rheumatology. 2019;58:10-21.
6. 6. Keefe FJ, Smith SJ, Buffington AL, et al. Recent advances and future directions in the biopsychosocial assessment and treatment of arthritis. J. Consult. Clin. Psychol. 2002;70:640-655.
7. 7. Uhlig T, Loge JH, Kristiansen IS, et al. Quantification of reduced health-related quality of life in patients with rheumatoid arthritis compared to the general population. J Rheumatol. 2007;34:1241-1247.
8. 8. Saketkoo LA, Pauling JD. Qualitative Methods to Advance Care, Diagnosis, and Therapy in Rheumatic Diseases. Rheum Dis Clin N Am. 2018;44:267-284.

9. 9. Kurimoto S, Yamamoto M, Shinohara T, et al. Favorable effects of explanatory illustrations attached to a self-administered questionnaire for upper extremity disorders. Qual Life Res. 2013;22:1145-1149.
10. 10. Kutlay S, Küçükdeveci AA, Gönül D, et al. Adaptation and validation of the Turkish version of the Rheumatoid Arthritis Quality of Life Scale. Rheumatol Int. 2003;23:21-26.
11. 11. Kaya BB, İçağasıoğlu A. Reliability and validity of the Turkish version of short form 36 (SF-36) in patients with rheumatoid arthritis. J Surg Med. 2018;2:11-16.
12. 12. Küçükdeveci AA, Sahin H, Ataman S, et al. Issues in cross‐cultural validity: Example from the adaptation, reliability, and validity testing of a Turkish version of the Stanford Health Assessment Questionnaire. Arthrit Care Res. 2004;51:14-19.
13. 13. Aydemir Ö, Guvenir T, Kuey L, et al. Validity and reliability of Turkish version of hospital anxiety and depression scale. Turk Psikiyatri Derg. 1997;8:280-287.
14. 14. Ünal E, Arın G, Karaca Nb, et al. Romatizmalı hastalar için bir yaşam kalitesi ölçeğinin geliştirilmesi: madde havuzunun oluşturulması. J Exerc Ther Rehabil. 2017;4:67-75.
15. 15. Woods JA, Vieira VJ, Keylock KT. Exercise, inflammation, and innate immunity. Immunol Allergy Clin North Am. 2009;29:381-393.
16. 16. Alpar R. Spor, sağlık ve eğitim bilimlerinden örneklerle uygulamalı istatistik ve geçerlik-güvenirlik: Detay yayıncılık; 2010.
17. 17. Matcham, Faith, et al. "Usefulness of the SF-36 Health Survey in screening for depressive and anxiety disorders in rheumatoid arthritis." BMC Musculoskel Dıs. (2016;17:1-10.
18. 18. Hayran M. Sağlık araştırmaları için temel istatistik: Omega Araştırma; 2011.
19. 19. Haroon N, Aggarwal A, Lawrence A, et al. Impact of rheumatoid arthritis on quality of life. Mod Rheumatol. 2007;17:290-295.
20. 20. Marra CA, Woolcott JC, Kopec JA, et al. A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med. 2005;60:1571-1582.
21. 21. Kosinski M, Keller SD, Hatoum HT, et al. The SF-36 Health Survey as a generic outcome measure in clinical trials of patients with osteoarthritis and rheumatoid arthritis: tests of data quality, scaling assumptions and score reliability. Med Care. 1999;37:10-22.
22. 22. Pincus T, Griffith J, Pearce S, et al. Prevalence of self-reported depression in patients with rheumatoid arthritis. Rheumatology. 1996;35:879-883.
23. 23. Dickens C, McGowan L, Clark-Carter D, et al. Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. Psychosom Med. 2002;64:52-60.
24. 24. Covic T, Cumming SR, Pallant JF, et al. Depression and anxiety in patients with rheumatoid arthritis: prevalence rates based on a comparison of the Depression, Anxiety and Stress Scale (DASS) and the hospital, Anxiety and Depression Scale (HADS). BMC psychiatry. 2012;12:1-10.
25. 25. Wells G, Boers M, Shea B, et al. Sensitivity to change of generic quality of life instruments in patients with rheumatoid arthritis: preliminary findings in the generic health OMERACT study. OMERACT/ILAR Task Force on Generic Quality of Life. Life Outcome Measures in Rheumatology. International League of Associations for Rheumatology. J Rheumatol. 1999;26:217-221.